Trial reportJournal of acquired immune deficiency syndromes (1999)2019
Baseline Characteristics Explain Differences in Effectiveness of Randomization to Daily Oral TDF/FTC PrEP Between Transgender Women and Cisgender Men Who Have Sex With Men in the iPrEx Trial.
Trial report in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Perceived influence of alcohol consumption, substance use, and mental health on PrEP adherence and condom use among PrEP-prescribed gay, bisexual, and other men-who-have-sex-with-men: a qualitative investigation.BMC public health · 2022Trial
- Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Review protocol for a systematic review and meta-analysis on HIV inequities in transgender and non-binary populations.BMJ open · 2025Article
- Mapping Community-Engaged Implementation Strategies with Transgender Scientists, Stakeholders, and Trans-Led Community Organizations.Current HIV/AIDS reports · 2023Review
- Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.The Journal of antimicrobial chemotherapy · 2022Article
- HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa.AIDS and behavior · 2022Article
- PrEP Use and Adherence Among Transgender Patients.AIDS and behavior · 2022Article
- Global scoping review of HIV prevention research with transgender people: Transcending from trans-subsumed to trans-centred research.Journal of the International AIDS Society · 2021Article
- Transporting Subgroup Analyses of Randomized Controlled Trials for Planning Implementation of New Interventions.American journal of epidemiology · 2021Article
- Risk compensation in HIV PrEP adherence among Black men who have sex with men in HPTN 073 study.AIDS care · 2021Article
- Understanding HIV Program Effects: A Structural Approach to Context Using the Transportability Framework.Journal of acquired immune deficiency syndromes (1999) · 2019Article
- Estimating preclinical amyloid positivity: A case study transporting ADNI to ARIC.Alzheimer's & dementia (New York, N. Y.)Article
- Management and Prevention of HIV Among Transgender Adults.Topics in antiviral medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.